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Abstract
Background: Prostate cancer is a leading cause of cancer-related death in men worldwide. Survivin is a member
of the inhibitor of apoptosis (IAP) protein family that is expressed in the majority of human tumors including
prostate cancer, but is barely detectable in terminally differentiated normal cells. Downregulation of survivin could
sensitize prostate cancer cells to chemotherapeutic agents in vitro and in vivo. Selenium is an essential trace
element. Several studies have shown that selenium compounds inhibit the growth of prostate cancer cells. The
objective of this study is to investigate whether survivin gene silencing in conjunction with selenium treatment
could enhance the therapeutic efficacy for prostate cancer and to elucidate the underlying mechanisms.
Methods: Expression of survivin was analyzed in a collection of normal and malignant prostatic tissues by
immunohistochemical staining. In vitro studies were conducted in PC-3M, C4-2B, and 22Rv1 prostate cancer cells.
The effect of selenium on survivin expression was analyzed by Western blotting and semi-quantitative RT-PCR.
Survivin gene knockdown was carried out by transfecting cells with a short hairpin RNA (shRNA) designed against
survivin. Cell proliferation was quantitated by the 3-(4,5-Dimethylthiazol-2-yl)- 2,5-Diphenyltetrazolium Bromide
(MTT) assay and apoptosis by propidium iodide staining followed by flow cytometry analysis. Finally, in vivo tumor
growth assay was performed by establishing PC-3M xenograft in nude mice and monitoring tumor growth
following transfection and treatment.
Results: We found that survivin was undetectable in normal prostatic tissues but was highly expressed in prostate
cancers. Survivin knockdown or selenium treatment inhibited the growth of prostate cancer cells, but the selenium
effect was modest. In contrast to what have been observed in other cell lines, selenium treatment had little or no
effect on survivin expression in several androgen-independent prostate cancer cell lines. Survivin knockdown
sensitized these cells to selenium growth inhibition and apoptosis induction. In nude mice bearing PC-3M
xenografts, survivin knockdown synergizes with selenium in inhibiting tumor growth.
Conclusions: Selenium could inhibit the growth of hormone-refractory prostate cancer cells both in vitro and
in vivo, but the effects were modest. The growth inhibition was not mediated by downregulating survivin
expression. Survivin silencing greatly enhanced the growth inhibitory effects of selenium.
Background
Prostate cancer (PCa) is the second most commonly
diagnosed cancer and the second leading cause of can-
cer deaths in men in the United States [1]. Surgery and
radiation therapy are effective for localized disease [2],
but there is no effective treatment strategy for recurrent
or metastatic PCa that has failed surgery, radiation or
hormonal therapy. Chemotherapeutic drugs could only
extend the lives of men with advanced prostate cancer
by months, and they are also associated with dose-
limiting toxicity. With the recent advances in the under-
standing of molecular pathways involved in prostate
cancer progression, targeted therapies that are designed
to interfere with the way cancer cells grow and survive
offer new hope in prostate cancer therapeutics.
Survivin, a structurally unique member of the inhibi-
tor of apoptosis (IAP) protein family, is involved in the
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[3]. It is abundantly expressed in cancer tissues but is
undetectable in normal, differentiated adult tissues.
Survivin expression is associated with poor prognosis in
many cancer types [4]. The expression of survivin
increases gradually from normal prostate tissue, to
primary low-grade prostate carcinoma, and to primary
high-grade carcinoma, with the highest expression
observed in foci of prostate cancer metastasized to the
lymph nodes [5]. This pattern of gene expression
suggests that survivin is associated with disease progres-
sion, and therefore making survivin an attractive target
for prostate cancer therapeutics.
Selenium is an essential trace element. Several case
control studies have demonstrated an inverse correlation
between serum selenium level and the risk of developing
prostate cancer [6-8]. The Nutritional Prevention of
Cancer (NPC) trial demonstrated that supplementation
of selenium, in the form of selenized yeast, could reduce
the incidence of prostate cancer by ~50% [9,10].
Although the interim analysis of the Selenium and Vita-
min E Chemoprevention Trial (SELECT) indicated no
reduction in prostate cancer risk associated with sele-
nium supplementation [11], the finding should not be
simply interpreted as selenium is ineffective against
prostate cancer. In the Discussion, we provide several
potential explanations for the discrepancy of the find-
ings in SELECT and the NPC trial. The negative
SELECT finding makes it more important and impera-
tive to study the efficacy of new selenium compounds
[12-14], including the compounds used in the study,
methylseleninic acid (MSA) and methylselenocysteine
(MSC), for prostate cancer intervention.
One of mechanisms proposed for the anticancer activ-
ity of selenium is apoptosis induction. Due to the role
of survivin in conferring cytoprotection against apopto-
sis in cancer cells, we set out to examine the effect of
s e l e n i u mo nt h ee x p r e s s i o no fs u r v i v i ni ns e v e r a lh o r -
mone refractory prostate cancer cell lines. To our sur-
prise, selenium treatment did not affect survivin
expression in these cells. Based on this finding, we
hypothesize that selenium treatment and survivin
knockdown would complement the action of each other,
leading to a greater anticancer effect. The present study
was designed to test this hypothesis, and to explore the
underlying mechanisms.
Methods
Reagents
MSA and MSC were obtained from PharmaSe (Lubbock,
TX). The rabbit anti-human polyclonal antibodies against
survivin and caspase 3 were from Santa Cruz Biotech
( S a n t aC r u z ,C A ) .T h er a b b i tanti-human Ki-67 polyclo-
nal antibody was obtained from Neomarker (Fremont,
CA). Trizol, RPMI 1640, fetal bovine serum (FBS), and
lipofectamine 2000 were purchased from Invitrogen
(Carlsbad, CA). Acridine orange (AO) and ethidium bro-
mide (EB) were from Sigma (St. Louis, MO).
Prostate tissue acquisition and immunohistochemical
(IHC) analysis
Prostate cancer specimens were obtained from patients
undergoing prostatectomy in the Second and the Third
Affiliated Hospitals of Jilin University. Normal prostate
tissues were obtained from patients undergoing surgery
for benign prostatic hyperplasia (BPH) in these hospi-
t a l s .T h i ss t u d yw a sa p p r o v e db yt h eR e s e a r c hE t h i c s
Committee of Norman Bethune College of Medicine,
Jilin University and was in compliance with the Hel-
sinki Declaration. The tissues were examined by the
pathologists to confirm the diagnosis before IHC ana-
lyses. All specimens were fixed in 10% formalin,
embedded in paraffin, and cut into 4 μm-thick slides.
The slides were dewaxed, and the endogenous peroxi-
dase activity was blocked by treatment with 3% hydro-
gen peroxide solution in methanol for 20 min. Epitope
retrieval was performed by treating the slides with
10 mM sodium citrate buffer (pH 6.0) and heating in a
microwave oven for two times at the high power for
6 min each. Non-specific binding was prevented by
blocking with normal goat serum (1:10) for 10 min.
Immunostaining of survivin was performed using a
rabbit anti-human survivin polyclonal antibody. Goat
anti-rabbit IgG conjugated with horseradish peroxidase
was used as the secondary antibody. The staining pro-
cedure was carried out manually at room temperature,
using an avidin-biotin-peroxidase complex method.
The presence of survivin and Ki-67 was evaluated by
staining with rabbit anti-survivin and anti-Ki-67 anti-
body, respectively. After incubation with the primary
antibody for 60 min, the slides were incubated with
the biotinylated goat anti-rabbit IgG (H+L) (DAKO,
Carpinteria, CA) at 37°C for 30 min, followed by incu-
bation with a 1:200 streptavidin-biotin-peroxidase
complex (Sigma, St. Louis) for 30 min. Reactive pro-
ducts were visualized with 3,3′-diaminobenzidene
(DAB) as the chromogen, and the slides were counter-
stained with hematoxylin and coverslipped. Sections
previously known to express survivin and Ki-67 were
included in each run, receiving either the primary anti-
body as the positive control, or a mouse IgG as the
negative control. The stained slides were analyzed with
a microscope at 200× magnification. The slides were
examined by two independent pathologists who had no
knowledge of the clinical outcomes and of the results
obtained by the other. Differences in interpretation
were reconciled by reviewing the slides jointly. Cellular
brownish staining was scored as positive and the
Liu et al. BMC Cancer 2010, 10:418
http://www.biomedcentral.com/1471-2407/10/418
Page 2 of 13threshold was set at 10%. The proliferation index was
defined as percent of tumor cells stained positively for
Ki-67.
Construction of the short hairpin RNA (shRNA) vectors for
survivin silencing
Oligonucleotides for anti-survivin shRNA expression
were designed, synthesized, and cloned into the pGCsi-
lencer-U6/Neo/GFP plasmid (GeneChem Co, Shanghai,
China). The sequences are: sense, 5′-gatcccGCAGTTT-
GAAGAATTAACCttcaagaga GGTTAATTCTTCAA
ACTGCtttttggat-3′; and antisense, 5′-agctatccaaaaaG-
CAGTTTGAAGAATTAACCtctcttgaaGGTTAATTC
TTCAAATGCgg-3′. Sequences in uppercase letters indi-
cate nucleotides 394-412 of the survivin cDNA. BLAST
searches of the human genome database were carried
out to ensure that the sequences would not target any
other transcripts. The recombinant plasmid was named
pGCsh-survivin (referred to as sh-survivin hereafter).
Recombinant pGCsh-scrambled plasmid (referred to as
sh-scrambled hereafter), which used a scrambled
sequence that has no significant homology to any
mouse or human gene sequences, was constructed as
the negative control.
Cell culture and transfection
The PC-3M, C4-2B, and 22Rv1 cells were cultured
in RPMI 1640 medium supplemented with 10% FBS,
100 unit/ml of penicillin, 100 μg/ml of streptomycin,
a n d2m Mo fL - g l u t a m i n ea n di n c u b a t e da t3 7 ° Ci n5 %
CO2. For transfection, 5 × 10
5 cells were plated onto
6-well plates 24 hours before transfection. Transfection
was performed using Lipofectamine 2000 according to
the manufacturer’s instructions. Transfection media
were removed 6 hours after transfection and replaced
with fresh complete medium containing 10% FBS.
Controls included lipofectamine 2000 treated cells and
sh-scrambled transfected cells.
Gene expression analysis by semi-quantitative reverse-
transcription PCR (RT-PCR) and Western analysis
The effects of survivin shRNA and MSA, alone or in
combination, on cellular expression of survivin were
measured by semi-quantitative RT-PCR and Western
blot analysis. PC-3M cells were divided into 5 groups:
(a) control (mock-transfected); (b) scrambled (trans-
fected with sh-scrambled); (c) sh-survivin (transfected
with sh-survivin); (d) MSA (treated with 5 μMM S A ) ;
(e) combination (transfected with sh-survivin and trea-
ted with 5 μM MSA), and cells were harvested after
66 hours following transfection and treatment. Total
RNA was isolated using the Trizol reagent according to
the manufacturer’s instructions. Survivin gene expres-
sion was determined by semi-quantitative RT-PCR,
using the primer pairs 5′-GAATTCATGGGTGCCCC-
GACGT TGCC-3′ and 5′-AGATCTTTCTTCTTATT
GTTGG TTTCC-3′. The housekeeping gene b-actin was
amplified as an internal standard.
For Western blot analysis, cells were lysed with
HEPES lysis buffer (30 mM HEPES, 1% Triton X-100,
10% glycerol, 5 mM MgCl2,2 5m MN a F ,1m ME D T A
and 10 mM NaCl). Fifty micrograms of protein were
electrophoresed on a 10% SDS-PAGE gel, transferred
onto a PVDF membrane (Millipore, Bedford, MA), and
probed with the anti-survivin or the anti-caspase-3 anti-
body. A goat anti-rabbit antibody labeled with horserad-
ish peroxidase (Amersham) was added as the secondary
antibody. Immunoblots were developed using a chemilu-
minescence detection system (Amersham Pharmacia
Biotech).
Cell proliferation and apoptosis assays
Cell numbers were determined at 66 hours after treat-
ment using the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphe-
nyltetrazolium bromide (MTT) assay and quantified by
using a microplate reader (Bio-Rad). For apoptosis, 10
6
cells were fixed in 70% (v/v) ethanol, stained with PBS
containing 50 μg/mL propidium iodide, 10 mg/mL
RNase, and 0.1% (v/v) Tween-20 for 30 minutes at
room temperature, and analyzed for cell apoptosis with
a FACScan flow cytometer (Becton Dickinson). For AP/
EB staining, PC-3M cells were collected by trypsiniza-
tion, washed with PBS (pH 7.4), and fixed in 4% parafor-
maldehyde. Fixed cells were washed twice with PBS and
resuspended in PBS containing 16 μg/ml AO and 16 μg/
ml EB, then mounted on a glass slide and observed
under a fluorescent microscope.
Antitumor effect of survivin siRNA and selenium in vivo
Five-week-old pathogen-free athymic nude mice were
purchased from the Institute of Laboratory Animal
Science, Chinese Academy of Medical Sciences (Beijing,
China). PC-3M cells in exponential growth phase were
harvested and single-cell suspensions (2 × 10
6 cells in
100 μl PBS) were injected subcutaneously (s.c.) into the
right dorsal flank of nude mice. Tumor size was mea-
sured every 2 to 3 days, and tumor volume calculated as
0.5236 × width
2 × length.A f t e rp a l p a b l et u m o r sh a d
developed, the mice were divided randomly into five
groups (six mice per group): (a) control (mock-trans-
fected); (b) scrambled (transfected with sh-scrambled);
(c) sh-survivin (transfected with sh-survivin); (d) MSC
(given MSC at 100 μg/mouse/day); (e) combination
(transfected with sh-survivin and given MSC). Transfec-
tion of the siRNAs was performed by an electroporation
method. Twenty micrograms of plasmid suspended in
50 μl PBS was injected percutaneously into the tumors
by using a syringe with a 27-gauge needle. Immediately
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tion generator (ECM830, BTX, Holliston, MA). Pulses
were delivered at a frequency of 1 pulse/sec, 150 V/cm,
for 50 milliseconds. This process was performed twice,
first on day 15 and then on day 25. For selenium treat-
ment, MSC was given by daily intragastric administra-
tion starting at day 15. Mice were sacrificed on day 35
when tumor burden in the control group approaching
10% of body weight. Tumors were excised, fixed in 4%
buffered formalin, and embedded in paraffin. The ani-
mal study was conducted following internationally
recognized guidelines and was approved by the Animal
Research Committee of Norman Bethune College of
Medicine, Jilin University.
Terminal deoxynucleotidyl transferase-mediated dUTP-
biotin nick end labeling (TUNEL) assay
Apoptotic cells in tissues were determined by using the
TUNEL assay (Roche Diagnostics, Indianapolis, IN)
according to the manufacturer’s instructions. Briefly,
after deparaffinization and rehydration, sections were
incubated with proteinase K (16.2 μg/mL in 10 mM
Tris·HCL, pH 7.4) for 20 min at 37°C. Slides were rinsed
with PBS and incubated with 3% H2O2 in methanol for
10 min at room temperature to block endogenous per-
oxidase activity, followed by PBS washing and incuba-
tion in 0.1% Triton X-100 in 0.1% sodium citrate for 2
min on ice. Sections were then incubated with a mixture
of terminal deoxynucleotidyl transferase (TdT) solution
and biotin-dUTP solution in a humidified chamber at
37°C for 60 min, followed by washing with PBS and
incubation with peroxidase-conjugated streptavidin in a
humidified chamber for 30 min at room temperature.
After an additional wash with PBS, the slides were incu-
bated in DAB and counterstained with hematoxylin.
Paraffin-embedded sections of normal tonsils were used
as positive control. Negative control was obtained by
replacing the TdT solution with distilled water. The pre-
sence of clear nuclear staining was indicative of apopto-
tic cells. At least 1,000 tumor cell nuclei were randomly
selected and examined. The number of TUNEL-positive
tumor cell nuclei was counted and the apoptotic index
was calculated as follows: apoptotic index = (number of
apoptotic cells/total cell number) × 100%.
Statistical analysis
Chi-square test was used to analyze the difference in
survivin expression between normal and cancerous
prostate tissues. Pearson correlation analysis was per-
formed to test the correlation of Gleason Score and
survivin expression in the prostate cancer cases. Data
were presented as mean ± standard deviation (SD)
when appropriate. Two-tailed Student’st -test was used
to evaluate the differences between treatment and
control values, and P < 0.05 was considered statistically
significant.
Results
Survivin is overexpressed in prostate cancer tissues
W ef i r s ta n a l y z e dt h ee x p r e s s i o no fs u r v i v i nb yI H C
staining in a collection of prostate cancer and normal
tissues in a Chinese cohort. As shown in Fig. 1, the sur-
vivin protein was virtually undetectable in normal pro-
static tissue but highly expressed in prostate cancer. The
cellular localization of survivin is mostly cytoplasmic,
but some weak staining can be found in the nucleus.
Overall, survivin was expressed in 24 of 28 (85.7%) pros-
tate cancer specimens, and no survivin expression could
be detected in 22 normal prostate tissues (Table 1). The
difference is statistically significant (P < 0.001). Pearson
correlation analysis identified a strong correlation
between Gleason score and survivin expression among
the cases (R = 0.7446, P < 0.0001). Please see additional
file-1 for the original data used to perform this analysis.
These results confirmed previous findings that survivin
is expressed in clinical prostate cancers [5], suggesting
survivin is a promising target for prostate cancer
therapy.
MSA induces apoptosis in PC-3M cells but has little effect
on survivin expression
Since MSA has been shown to induce apoptotic cell
death in a number of prostate cancer cell lines [15,16],
we set out to examine the effect of MSA on apoptosis
in PC-3M cells. PC-3M is a metastatic subline derived
from PC-3. We chose PC-3M because it has the highest
level of survivin expression among the cell lines we have
tested (data not shown). Cells were treated with 5 μM
MSA for 48 and 66 hr and the extent of apoptosis was
quantified by flow cytometric analysis of cells labeled
with propidium iodide (PI). This dose of selenium has
been shown to be achievable in human subjects taking
selenium supplementation [17]. As shown in Fig 2, only
0.9% of the control cells were positively labeled with PI.
In cells treated with MSA, the proportion of apoptotic
cells increased to 3.6% by 48 hr, and to 14.7% by 72 hr.
These results showed that MSA was capable of inducing
apoptosis in PC-3M cells, but the effect was modest and
a long treatment (>48 hr) was needed to achieve a
significant induction of apoptosis.
As a member of the IAP family, the best known func-
tion of survivin is to protect the cells from undergoing
apoptosis. It has been shown that selenium decreased
survivin expression in several prostate cancer cell lines,
including LNCaP, PC-3, and C4-2 [18]. We decided to
examine survivin expression in PC-3M cells following
MSA treatment. In contrast to what have been observed
in other cell lines, both semi-quantitative RT-PCR and
Liu et al. BMC Cancer 2010, 10:418
http://www.biomedcentral.com/1471-2407/10/418
Page 4 of 13Western blotting analysis showed that treatment with
5 μM MSA for 66 hr did not influence survivin expres-
sion in PC-3M cells (Fig. 3A &3B), indicating the induc-
tion of apoptosis by MSA in these cells is not mediated
by decreasing survivin expression. In addition to PC-3M
cells, we analyzed survivin expression in C4-2B and
22Rv1 prostate cancer cells following MSA treatment
and the results were similar (Fig. 3B).
Survivin gene silencing sensitizes prostate cancer cells to
growth inhibition by MSA
Based on the data from the previous experiments, we
hypothesized that survivin knockdown will sensitize
prostate cancer cells to growth inhibition by MSA. To
test this hypothesis, we designed a plasmid-based
shRNA vector for survivin gene silencing and tested its
efficacy. As shown in Fig. 3A, sh-survivin effectively
reduced the level of the survivin transcript, whereas the
scrambled shRNA had no effect. Western blotting analy-
sis confirmed the down-regulation of survivin expression
by sh-survivin in all 3 cell lines (Fig. 3B). Quantitation
by volume densitometry showed the knockdown effi-
ciency at the protein level is in the range of 60-70% in
these cell lines.
We next quantitated changes in cell viability after cells
were transfected with the shRNAs and treated with var-
ious concentrations of MSA for 66 hr. The results are
shown in Fig. 4. Cells transfected with sh-scrambled
have similar viability as the mock-transfected control
cells under all circumstances. Silencing of survivin
reduced cell viability by 50-60% (P <0 . 0 1 ) .I nt h e
absence of sh-survivin, MSA reduced the cell viability in
a dose-dependent manner in all three cell lines. How-
ever, cells transfected with sh-survivin are significantly
more sensitive to MSA growth inhibition, manifested by
the marked downward shift of the dose-response curves.
In addition, cells transfected with sh-survivin and
Figure 1 Representative images from immunohistochemical analysis of survivin expression in normal and cancerous prostatic tissue.
A, normal prostate. B, prostate cancer. The images were obtained at 200× magnification.
Table 1 Expression of survivin in normal and cancerous
prostatic tissues
Tissue Type survivin staining status P
positive N (%) negative N (%)
Normal 0 (0%) 22 (100%)
<0.001
Prostate cancer 24 (85.71%) 4 (15.29%)
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Page 5 of 13Figure 2 MSA induces apoptosis in PC-3M cells. Untreated cells (A) or cells treated with 5 μM MSA for 48 hr (B) or 72 hr (C) were labeled
with propidium iodide (PI) and the histograms of DNA content were obtained by flow cytometry analysis. The x-axis indicates PI fluorescence
intensity, and y-axis indicates cell number. The numbers above the histogram are percentage of cells in the sub-G1 (apoptotic) phase.
Figure 3 Survivin expression in various prostate cancer cells treated with MSA, sh-survivin, or the combination.A ,R T - P C Ra n a l y s i si n
PC-3M cells. B, Western blot analysis in PC-3M, C4-2B, and 22Rv1 cells. The band intensity was quantified by volume densitometry and
normalized to that of b-actin. The results are expressed as fold induction over untreated.
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significantly greater than sh-survivin alone (P < 0.01).
Survivin gene silencing enhances selenium’s efficacy on
apoptosis induction
Next, we analyzed the effect of apoptosis induction by
sh-survivin and MSA in PC-3M cells by flow cytometry.
Transfection and MSA treatment were carried out as
described in the previous section. Very few PI-positive
cells were found in untreated cells or in cells transfected
with sh-scrambled (Fig. 5A). Silencing of survivin
resulted in a robust increase of apoptotic cells, confirm-
ing the antiapoptotic role of survivin. The combination
of survivin knockdown and MSA induced apoptosis
more effectively than either alone (P < 0.01). In addition,
AO/EB staining was performed to visualize the apopto-
tic cells and similar results were obtained (see additional
file-2 for detail).
Caspases are important mediators of apoptosis. Acti-
vation of caspase-3 by enzymatic cleavage is a hallmark
Figure 4 Growth inhibition by survivin knockdown and MSA treatment. PC-3M, C4-2B, and 22Rv1 cells were transfected with the shRNAs
and treated with various concentrations of MSA for 66 hr. Cell numbers were quantitated by the MTT assay. The viability of the mock-
transfected control cells were set arbitrarily to 100% and the viabilities of other samples were expressed as percentage of the control. The data
presented are mean ± SD (n = 18). Control, mock-tranfected cells. Sh-scrambled, cells transfected with sh-scrambled. Sh-survivin, cells transfected
with sh-survivin. *, P < 0.01 vs MSA alone; #, P < 0.01 vs sh-survivin alone.
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caspase-3 activation by Western blotting and the results
are shown in Fig. 5B. Cleaved caspase-3 (19 KDa) was
induced similarly by sh-survivin and MSA, whereas their
combination led to a modestly but significantly stronger
activation (P < 0.05). The changes in caspase-3 activa-
tion did not involve changes in gene expression, as the
band intensity for procaspase-3 (32 KDa) was not chan-
ged by either sh-survivin, or MSA, or their combination.
The modest increase in caspase-3 activation in the
combined group suggest that the synergistic effect on
apoptosis induction could also be mediated by caspase-
independent mechanisms, since survivin has also been
shown to inhibit both caspase-independent apoptosis
[19]. In general, the apoptosis data are in agreement
with the MTT results, showing that survivin gene
knockdown greatly enhances the anticancer effect of
selenium in prostate cancer cells.
Inhibition of tumor growth in vivo by survivin knockdown
and selenium
A xenograft nude mouse tumor model with subcuta-
neously implanted PC-3M cells was used to investigate
the effects of survivin knockdown and selenium in vivo.
Fifteen days after injection, the tumors reached an aver-
age volume of 122.5 ± 15.36 mm
3. The animals were
then randomly divided into 5 groups receiving PBS,
sh-scrambled, sh-survivin, MSC, or the combination of
MSC and sh-survivin, respectively. MSC was admini-
s t r a t e da tad o s eo f1 0 0μg/mouse/day through an oral
route and the shRNA plasmids were delivered by elec-
troporation twice during the experiment, first at day 15
Figure 5 Apoptosis induction by survivin knockdown and MSA treatment in PC-3M cells. Cells were transfected with the shRNAs and
treated with 5 μM MSA for 66 hr. A, Quantitation of apoptotic cells by PI staining and flow cytometry analysis. Apoptosis index was calculated
as percentage of cells in the sub-G1 population on the DNA histogram. The data presented are mean ± SD (n = 3). The values are 0.9% ± 0.65%,
2.8% ± 0.71%, 23.1 ± 2.36%, 12.7 ± 1.45%, and 38.6 ± 2.87%, respectively. B, Western blot analyses of caspase-3. b-actin was used as the loading
control. B. Quantitation of cleaved caspase-3 by volume densitometry. The intensity of the cleaved caspase-3 band was quantified by volume
densitometry and normalized to that of b-actin. The result was expressed as fold to control.
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grafts in the control and the scrambled groups grew at
similar rates, whereas xenografts in all 3 treatment
groups demonstrated reduced growth by day 30, when
compared to their respective controls (P < 0.05). Consis-
tent with the in vitro results, selenium by itself has a
modest inhibitory effect on the growth of PC-3M xeno-
grafts, but the combination with survivin knockdown
achieved a robust growth inhibition. In fact, tumors in
the combination group maintained their original sizes
after treatment, and were significantly smaller than
those in the single treatment groups by day 35 (P <
0.05). Similar conclusions can be reached by examining
the final tumor weight (Fig. 6B). These results demon-
strate a strong inhibitory effect on tumor growth in vivo
by the combination of survivin knockdown and sele-
nium treatment.
To explore the mechanisms of tumor inhibition
in vivo, tumors were collected after the animals were
sacrificed. The expression of survivin was first analyzed
Figure 6 Inhibition the growth of PC-3M xenografts by survivin knockdown and MSA. The shRNA plasmids were transfected by
electroporation twice at day 15 and 25, as indicated by the arrows. A, tumor volume. B, final tumor weight. The data presented are mean ± SD
(n = 6).*, P < 0.05 vs control; **, P < 0.05 vs sh-scrambled; #, P < 0.05 vs sh-survivin; &, P < 0.05 vs MSC group.
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results showed that the electroporation-based delivery
method was effective as survivin was down-regulated by
sh-survivin. MSC has no effect on the expression or the
cellular localization of survivin. Cell proliferation was
quantitated by IHC staining of Ki-67 (Fig. 7B) and apop-
totic cells were identified by the TUNEL assay (Fig. 7C).
Tumors from the control or the sh-scrambled groups
have proliferating cells (Ki-67 positive) and less apopto-
tic cells (TUNEL positive) than those in the sh-survivin
or MSC. The lowest number of proliferating cells and
highest number of apoptotic cells were found in tumors
from the combination group. Quantitative analyses of
the stained slides were performed and the results are
summarized in Table 2. In tumors receiving sh-survivin
or MSC, the proliferation index was significantly lower
(P < 0.01), and the apoptotic index was significantly
higher (P < 0.01), when compared with the control
t u m o r s .O n c ea g a i n ,t h ec o m b i n a t i o ng r o u pw a sm o r e
effective in blocking tumor growth and inducing cell
death than either of the single treatment groups (P <
0.01). These results confirmed our in vitro observations
and showed survivin knockdown greatly enhanced the
efficacy of selenium in inhibiting the growth of prostate
cancer cells in vivo.
Discussion
Soon after the development of the RNA interference
(RNAi) technology a few years ago, the potential of
using this highly specific and powerful gene silencing
approach in treating cancer has generated a great deal
of interest. Obviously, the key to the success of this
approach is to identify a gene which is expressed univer-
sally in cancer cells, but not in normal cells. Survivin
appears to be such a candidate. As a member of the IAP
family, survivin has been reported to be up-regulated in
human cancers of various origins. Consistent with pre-
vious reports [5,20], we found in the present study that
survivin is highly expressed in the majority of cancerous
prostate tissues, but not in normal prostatic tissues.
Silencing of survivin expression in PC-3M cells by a
specific shRNA led to decreased cell growth and
increased cell death. Elevated survivin expression has
been associated with resistance to chemotherapeutic
agents [21-24]. Therefore, targeted suppression of survi-
vin expression represents a potential therapeutic strategy
for prostate cancer, either being used alone or in a
neoadjuvant setting.
Several potential reasons have been discussed to
explain the discrepancy of the findings in SELECT and
the NPC trial. One important consideration is the
sh-scrambled control sh-survivin combination MSC
TUNEL
survivin
Ki-67
Figure 7 Immunohistochemical staining in PC-3M tumor xenografts. (A) survivin expression, (B) Ki-67 expression, and (C) TUNEL assay. The
images were taken at 200 × magnification.
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Page 10 of 13baseline selenium level. The NPC trial showed that the
protective effect of selenium was limited to patients
with baseline serum selenium in the lower 2 tertiles
[25]. The average baseline selenium level of the partici-
pants in SELECT was much higher than that observed
in the NPC study. In fact, 78% of men in SELECT had
baseline selenium above the range that selenium pro-
vided protection in the NPC trial (<121.6 ng/ml) [11].
Another important consideration is how selenium exerts
its anticancer activity. By using a nested case-control
design within a prospective study (the Physicians’ Health
Study) among 586 men diagnosed with prostate cancer
during 13 years of follow-up and 577 control subjects,
Li et al. showed a ~50% reduction in risk of advanced
prostate cancer in individuals within the highest quintile
of selenium level compared to those within the lowest
quintile [26]. Such association was not observed for
localized prostate cancer, suggesting that selenium
might function by slowing down tumor progression
[26]. In view of the above information, we believe that
the negative finding by SELECT should not be simply
interpreted as selenium is ineffective against prostate
cancer; instead, it raises the hypothesis of whether sele-
nium might only be effective only in selected subsets of
men with lower selenium levels at baseline.
The formulation and dose of selenium used in the
SELECT study have also been hot topics of debate. The
compounds used in the current study, MSA and MSC,
are monomethylated forms of selenium and are consid-
ered second-generation selenium compounds. Metaboli-
cally, they are very different from selenomethionine, the
formulation used in the SELECT. MSA and MSC can be
easily converted to methylselenol, which is considered
to be the critical metabolite for the anticancer activity of
selenium [14,27]. Selenomethionine, on the other hand,
can be incorporated nonspecifically into proteins in
place of methionine [14]. Due to its compartmentation
into tissue proteins, selenomethionine is not as readily
available as MSA or MSC for further metabolism. The
metabolism of selenomethionine to methylselenol
requires at least 5 transsulfuration steps and the action
of thiol methyltransferase [12-14]. Studies published
prior to and after the start of the SELECT study have
showed that MSA and MSC have stronger anticancer
activities than selenomethionine [28-30].
Several studies have shown that selenium induces
growth arrest and cell death in prostate cancer cells and
inhibits the growth of prostate cancer xenografts
[15,16,31,32], leading support to the idea that selenium
could be used in the treatment of prostate cancer. In
the present study, we confirmed the anticancer activity
of selenium in the androgen-independent human pros-
tate cancer cells. In contrast to a report that selenium
suppresses survivin expression in a number of PCa cell
lines, including the parental PC-3 and LNCaP lines [18],
our in vitro and in vivo data both showed that MSA
treatment had little or no effect on survivin expression
in PC-3M, C4-2B, and 22Rv1 cells. This is consistent
with results published by Azrak et al showing at similar
doses, selenium treatment did not affect survivin expres-
sion in mouse prostate cancer cells or ovarian cancer
cells [33,34]. When useda l o n e ,M S Ah a dam o d e s t
effect on growth inhibition and apoptosis induction in
PC-3M cells cultured in vitro. Similarly, MSC inhibited
the growth of PC-3M xenografts but the efficacy appears
to be inferior to its inhibitory effect against PC-3 xeno-
grafts [29]. The insensitivity of PC-3M cells to selenium
could be related to its inability to suppress survivin
expression in these cells. Ins u p p o r to ft h en o t i o n ,w e
found that the effect of selenium was greatly enhanced
when survivin expression was silenced. Indeed, in nude
mice bearing PC-3M xenografts, survivin knockdown in
combination with selenium treatment stopped tumor
growth completely. In the study by Azrak et al which
showed MSA did not inhibit survivin expression in
skov3 ovarian cancer cells, survivin knockdown greatly
enhanced the efficacy of combination therapy by MSA
and paclitaxel, converting the interaction between these
two agents from antagonistic to synergistic [34].
Conclusions
Survivin was highly expressed in clinical prostate can-
cers but not in normal prostates. In prostate cancer
cells where selenium had no effect on survivin expres-
sion, growth inhibition and apoptosis induction effects
of selenium were modest. Both the in vitro and in vivo
efficacies of selenium were greatly enhanced when survi-
vin expression was silenced. The current study suffers
from the limitation that the results are obtained mainly
from cell culture and animal experiments. Nonetheless,
the results suggest a potential mechanism of cancer cell
resistance to the cytotoxic effect of selenium compounds
and a strategy to improve the efficacy of selenium. This
is important, especially in the context of the negative
findings of the SELECT trial with regard to the antican-
cer activity of selenium. Further preclinical studies are
Table 2 Cell proliferation and apoptosis indices from
PC-3M xenografts
Group (n = 6) Proliferation index Apoptotic index
control 86.75 ± 9.43 3.64 ± 1.66
sh-scrambled 81.64 ± 9.25 4.45 ± 1.86
sh-survivin 16.82 ± 5.32* 31.3 ± 3.64*
MSC 56.2 ± 8.65* 14.7 ± 2.23*
Combination 6.8 ± 1.64*
# 48.6 ± 2.67*
#
*, P < 0.01 vs sh-scrambled; #, P < 0.01 vs sh-survivin or MSC group.
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Page 11 of 13needed to confirm the findings before these results can
be incorporated into clinical practice.
Additional material
Additional file 1: This file contains the original data used for the
Pearson correlation analysis for survivin expression and Gleason
score. It also contains the PSA measurements.
Additional file 2: This file contains additional figure for apoptosis
detection using AO/EB staining as described in the text.
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